Buck-Founded Aeovian Pharmaceuticals doses first participants in Phase I trial

Aeovian also raises $50M to advance novel science

Aeovian Pharmaceuticals, a clinical-stage biopharmaceutical company developing novel and highly selective therapeutics that potentially inhibit the mTORC1 pathway, today announced that it has dosed the first cohort of participants for a Phase I study for the treatment of seizures associated with Tuberous Sclerosis Complex. Aeovian also announced they have procured $50M in investment to drive this and other projects forward.  Additionally, Aeovian announced a recently completed $50M financing, led by Hevolution.

The Buck Institute for Research on Aging is proud to be the original founder of Aeovian, formerly known as Delos Pharmaceuticals, and remains a shareholder.  Aeovian was incubated at the Buck Institute campus for several years.

“We are delighted to see Buck Institute geroscience and ingenuity catalyze the creation of promising companies like Aeovian,” said Eric Verdin, MD, CEO of the Buck Institute. “Our work and dedication to identifying novel aging pathways and the ability to modulate them is what has made the Buck such a driver in the field of the biology of aging.  The subsequent work that Aeovian has done to identify and develop novel candidates such as AV078 is remarkable.  They are to be commended for leading the way in developing candidates for such an important biological mechanism such as TOR. We eagerly await to see what this remarkable team will accomplish in applying it to unmet medical needs and aging, in general.”

About Aeovian 
Aeovian Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted and highly selective small molecules to restore cellular metabolic quality control, thereby addressing the dysregulated growth and hyperactive signaling found in certain rare genetic and age-related diseases. Our lead development candidate, AV078, is a first-in-class CNS penetrant selective mTORC1 inhibitor being developed for the treatment of TSC refractory epilepsy and is currently being evaluated in a Phase 1 trial. TSC is a rare genetic disorder caused by the hyperactive signaling of mTORC1. Beyond AV078, we have developed a proprietary library of small molecules, which are potent and selective inhibitors of either mTORC1 or CD38 and have the potential to precisely target the underlying biology of multiple rare and age-related diseases. For more information, please visit our website at www.aeovian.com.